Top news of the week: 03.08.2021.
Healthcare
‘We’ve been instrumental’: How Seattle became a hub for COVID-19 vaccine research
When the COVID-19 pandemic hit, University of Washington scientist Deborah Fuller did a quick pivot to the new virus. Her skills in vaccine research had been honed for many years on HIV…
Retired neurologist with Alzheimer’s knows firsthand the risks of Biogen’s new drug
For all the attention focused on the disputed benefits of the Biogen medicine, Daniel Gibbs says an important aspect of Aduhelm has been downplayed ― its risks.
“In the first stages of the pandemic we had to keep people out of the labs and had to stall clinical trials,” he says. “Even now we can only have a few scientists in at any one time, so people have to work shifts, including nights and weekends.”
Cancer research has a bright future in the UK, but only if the government can implement a clear funding pan, says the ICR's Paul Workman
Why the life sciences leave people of color behind
And how COVID-19 and the Black Lives Matter movement could mark a turning point.
28 Jul Complix Signs Global Drug Discovery and Development Agreement with Jiangsu Nhwa Pharmaceutical Co. to Develop Novel Alphabody Therapeutics for Treatment of CNS Diseases
Hasselt, July 28, 2021 – Complix, a biopharmaceutical company developing a pipeline of transformative Alphabody therapeutics, today announced that it has signed a global …
The evolution of the SARS-COV-2 virus is a stark reminder that research and innovation must continue (Step #5)
Developing COVID-19 vaccines in less than a year was a monumental achievement – but to improve the efficacy, manufacture and distribution of vaccines and combat emerging variants, ...
2007: First production of spider silk through biotechnology
Spider silk has long been hailed for its properties, the ultimate biomaterial, however production from spiders directly on a scale large enough for industrial use has always been …